Emma C. Scott - Concepedia

Author

Emma C. Scott

Oregon Health & Science University ORCID

Also Known As

E Scott, E. Scott, E.C. Scott, Emma C Scott, Emma C. Scott, Emma Catherine Scott, Emma Scott, Hang Quach, Hari, Parameswaran, Sebag, Michael

Publications

Citations

H-Index

Concepts

All Affiliations

Oregon Health & Science University University of Pennsylvania Memorial Sloan Kettering Cancer Center Levine Cancer Institute Hackensack University Medical Center

About

Emma C. Scott is an author at Oregon Health & Science University specializing in medicine, oncology, and hematology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	10	2K
2	Health Sciences	2	2	46
3	Blood Transplantation	1	1	84
4	Cell Biology	1	1	365
5	Epidemiology	1	1	84

Emma C. Scott

Publications

6.9K

Citations

H-Index

Page 1

	Year	Citations
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma Stephen M. Ansell, Alexander M. Lesokhin, Ivan Borrello, New England Journal of Medicine	2014	3.5K
Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial Sagar Lonial, Brendan M. Weiss, Saad Z. Usmani, The Lancet Hematological MalignancyOncologyDaratumumab MonotherapyImmunologyClinical Trials	2016	842
Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy Ujjawal H. Gandhi, Robert F. Cornell, Arjun Lakshman, Leukemia Hematological MalignancyOncologyMultiple Myeloma RefractoryImmunologyHematology	2019	597
Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma Paul G. Richardson, Susanna Jacobus, Edie Weller, New England Journal of Medicine	2022	428
Combined autophagy and proteasome inhibition Dan T. Vogl, Edward A. Stadtmauer, Kay-See Tan, Autophagy MitophagyImmunologyProteasomeCell DeathPharmacotherapy	2014	365
Daratumumab plus bortezomib and dexamethasone <i>versus</i> bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR Andrew Spencer, Suzanne Lentzsch, Katja Weisel, Haematologica	2018	254
Improved Outcomes After Autologous Hematopoietic Cell Transplantation for Light Chain Amyloidosis: A Center for International Blood and Marrow Transplant Research Study Anita D’Souza, Angela Dispenzieri, Baldeep Wirk, Journal of Clinical Oncology	2015	200
Preliminary Results of a Phase I Study of Nivolumab (BMS-936558) in Patients with Relapsed or Refractory Lymphoid Malignancies Alexander M. Lesokhin, Stephen M. Ansell, Philippe Armand, Blood	2014	125
Older Patients with Myeloma Derive Similar Benefit from Autologous Transplantation Manish Sharma, Mei‐Jie Zhang, Xiaobo Zhong, Biology of Blood and Marrow Transplantation Transplantation MedicineImmunologyAutologous TransplantationMyeloid NeoplasiaHematological Malignancy	2014	84
Talquetamab plus Teclistamab in Relapsed or Refractory Multiple Myeloma Yaël C. Cohen, Hila Magen, Moshe E. Gatt, New England Journal of Medicine	2025	70

Page 1